different glp-1 Classification of RAs based on parameters [13] GLP-1 Receptor Agonists as Treatments

doi: 10.1016/j.cmet.2015.05.012

Targeted agents like 5-HT4 agonists (tegaserod, prucalopride), guanylate cyclase-C agonists (linaclotide), and NHE3 inhibitors (tenapanor) modulate motility and pain signaling but face limitations such as side effects (e.g., diarrhea, cardiovascular risks) or insufficient long-term data

H., Francis R

Thats a public health argument

Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction 1-6

And more importantly, when the study participants were given all-you-can-eat ham sandwiches a few hours later, they ate significantly less